Legal & General Group Plc Has $3.76 Million Holdings in Dr.Reddy's Laboratories Ltd (RDY)

Legal & General Group Plc lowered its position in Dr.Reddy's Laboratories Ltd (NYSE:RDY) by 5.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 105,375 shares of the company’s stock after selling 5,900 shares during the quarter. Legal & General Group Plc owned about 0.06% of Dr.Reddy's Laboratories worth $3,759,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in the business. Sivik Global Healthcare LLC acquired a new position in shares of Dr.Reddy's Laboratories during the third quarter valued at approximately $1,784,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Dr.Reddy's Laboratories by 4.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 264,692 shares of the company’s stock valued at $9,444,000 after acquiring an additional 11,983 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Dr.Reddy's Laboratories by 19.6% during the third quarter. Bank of New York Mellon Corp now owns 33,796 shares of the company’s stock valued at $1,206,000 after acquiring an additional 5,541 shares during the period. Alps Advisors Inc. increased its stake in shares of Dr.Reddy's Laboratories by 29.9% during the third quarter. Alps Advisors Inc. now owns 28,476 shares of the company’s stock valued at $1,016,000 after acquiring an additional 6,550 shares during the period. Finally, Aperio Group LLC increased its stake in shares of Dr.Reddy's Laboratories by 11.3% during the third quarter. Aperio Group LLC now owns 181,974 shares of the company’s stock valued at $6,493,000 after acquiring an additional 18,459 shares during the period. Institutional investors own 13.71% of the company’s stock.

Dr.Reddy's Laboratories Ltd (NYSE RDY) opened at $36.16 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.46 and a quick ratio of 1.08. The stock has a market cap of $6,032.62, a P/E ratio of 35.32 and a beta of 0.39. Dr.Reddy's Laboratories Ltd has a 12-month low of $29.83 and a 12-month high of $46.95.

A number of research analysts recently commented on the stock. Zacks Investment Research upgraded shares of Dr.Reddy's Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 26th. Jefferies Group lowered their price objective on shares of Dr.Reddy's Laboratories from $31.62 to $30.51 and set an “underperform” rating on the stock in a research note on Wednesday, November 1st. Morgan Stanley upgraded shares of Dr.Reddy's Laboratories from an “equal weight” rating to an “overweight” rating in a research report on Thursday, September 21st. Finally, CLSA upgraded shares of Dr.Reddy's Laboratories from an “underperform” rating to an “outperform” rating in a research report on Thursday, August 31st. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $30.51.

ILLEGAL ACTIVITY WARNING: “Legal & General Group Plc Has $3.76 Million Holdings in Dr.Reddy's Laboratories Ltd (RDY)” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at https://www.com-unik.info/2017/12/23/legal-s-laboratories-ltd-rdy.html.

Dr.Reddy's Laboratories Company Profile

Dr. Reddy’s Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

Want to see what other hedge funds are holding RDY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dr.Reddy's Laboratories Ltd (NYSE:RDY).

Institutional Ownership by Quarter for Dr.Reddy's Laboratories (NYSE:RDY)

Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit